ClinicalTrials.gg
Active, not recruitingNCT04937400Updated Oct 23, 2026

Delirium in Children Undergoing Stem Cell Transplantation

An observational study in Stem Cell Transplant Complications and Delirium, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 6 sites in 2 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Weill Medical College of Cornell University · Observational

How we know

Updated Oct 23, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,040
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Delirium with a site in United States — 37 open to participants now, 60 under way, 7 of them phase 3. Delirium · United States.

Enrollment
5th of 69
1,040 · median 124
Started
2021
with 12 others
Observational
69 of 263
10 open now
Primary completion
2026-10
later than 21 of 59 live
Registered
197th of 263
by date

Among the 263 studies in Delirium with a site in United States, this one is the 5th largest by enrollment of the 69 observational ones that give a count, is one of 13 that started in 2021, is one of 69 observational ones, reaches primary completion later than 21 of the 59 other live ones, and was the 197th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

37 of the 263 studies in Delirium with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Delirium with a site in United States, or all of them as a file.
02

Study summary

Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.

Read the detailed description

Delirium -- defined as an acute change in awareness and cognition that occurs in the setting of an underlying illness -- is a common complication of hematopoietic stem cell transplantation (HSCT) in adults, with associated morbidity and mortality. This has never been studied in children, where risk factors may vary substantially from adults. The objectives of this study are: to define the epidemiology of delirium, and measure its effect on outcomes.

This prospective longitudinal cohort study will prospectively establish the incidence of delirium in 1000 children in the peri-transplant period, and identify modifiable risk factors that predispose to delirium development. This study will also define the effect of delirium on important clinical outcomes, including neurocognitive function. This study will be executed by a research consortium of five leading pediatric oncologic transplant centers in North America, in collaboration with the leading pediatric delirium research group in the United States.

This innovative proposal will leverage the combined experience of the pediatric delirium and HSCT teams to expand urgently needed delirium research into a unique and unstudied population. By reducing delirium rates, outcomes after pediatric HSCT can be optimized.

03

Conditions studied

  • Stem Cell Transplant Complications
  • Delirium

Browse trials for

Keywords

  • pediatric
  • stem cell transplant
  • outcomes
  • epidemiology
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects will include all patients admitted to the five participating pediatric stem cell transplant sites for the purpose of HSCT during the study period. Enrollment goal is 1000 subjects overall, and 240 subjects for neurocognitive testing. Subjects will be seriously ill. Every patient admitted for HSCT will be eligible for inclusion, unless they are >21 years old. Subjects will be enrolled regardless of gender, race, or ethnicity. No subgroups will be excluded, as delirium likely affects children of all ages and developmental trajectories, with no predilection based on gender, race, or ethnicity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 0-21 years old
  • Admitted for purpose of stem cell transplant

Exclusion criteria

Exclusion Criteria:

  • Age >21 years old
  • Admitted for reason other than stem cell transplant (example: late post-transplant complications).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,040 participants (actual)
Patient registry
No

Groups and cohorts

  • Pediatric Stem Cell Transplant Patients

    A consecutive cohort of children admitted to the hospital for stem cell transplantation

    Other: Daily screening for delirium

Interventions

  • OtherDaily screening for delirium

    Each child will be screened twice daily for delirium throughout the transplant hospitalization

    Also known as: Cornell Assessment for Pediatric Delirium

06

What researchers measure

Primary outcomes

  1. Delirium incidence

    Number of patients who develop delirium during the course of their transplant hospitalization

    Time frame: 1-50 days

Secondary outcomes

  1. Hospital length of stay

    Length of transplant hospitalization will be measured in days.

    Time frame: 1-365 days

  2. Mortality rate

    Count will include number of patients with either in-hospital or post-discharge mortality.

    Time frame: 1-5 years

  3. Readmission rate

    Count will include number of patients who are readmitted to the hospital within 30-days of discharge.

    Time frame: 1-365 days

  4. Change in neurocognitive functioning as measured by the NIH Toolbox Cognition Battery

    Neurocognitive functioning will be measured by the NIH Toolbox Cognition Battery, and reported as a total composite score ranging from 50-150. An average score, adjusted for age, is 100. A score lower than 100 indicates lower cognitive functioning than average; a score higher than 100 indicates higher cognitive functioning than average.

    Time frame: pre-transplant, 3 months after transplant, 12 months after transplant

07

Study locations

6 sites
08

References and documents

Publications

  • Traube C, Gerber LM, Mauer EA, Small K, Broglie L, Chopra YR, Duncan CN, Ebens CL, Fitzgerald JC, Freedman JL, Hudspeth MP, Hurley C, Mahadeo KM, McArthur J, Shapiro MC, Sharron MP, Wall DA, Zinter MS, Greenwald BM, Silver G, Boulad F. Delirium in Children Undergoing Hematopoietic Cell Transplantation: A Multi-Institutional Point Prevalence Study. Front Oncol. 2021 Apr 22;11:627726. doi: 10.3389/fonc.2021.627726. eCollection 2021. PubMed 33968727 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will be shared via NIH-approved repositories within 12 months after publication of primary results. The sharing of unpublished information may be subject to confidentiality issues and will need to be discussed with the appropriate institutions before any request is granted. Access will be granted to qualified researchers with a methodologically sound proposal and appropriate agreements, for academic research, meta-analyses, and other approved studies.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified IPD will be available no later than 12 months after publication of the primary results and for at least 5 years thereafter.

Access criteria: Access will be granted to qualified researchers with a methodologically sound proposal. Researchers must agree to a data use agreement, and requests will be reviewed by the study team and the Data Coordinating Center.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2026, 62 months.

Of 177 non-industry observational studies under Delirium, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 62 months is above that.

Counting every sponsor, half of 179 studies reached it within 20 months; a quarter within 11 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Oct 2026 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2021
First posted
Jun 24, 2021
StartActual
Jul 12, 2021
Primary completionActual
Oct 1, 2026was Jul 2026
CompletionEst.
Jul 31, 2027was Jul 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2026→Oct 1, 2026 (actual)
Oct 23, 2026
Study completion
Jul 31, 2026→Jul 31, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Jul 30, 2026→Oct 1, 2026 (now actual)
    Study completion Jul 31, 2026→Jul 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04937400
Responsible party
Sponsor
First posted
Jun 24, 2021
Start date
Jul 12, 2021
Primary completion
Oct 1, 2026
Completion
Jul 31, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Chani Traube
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion